Mazahir Alimohamed
Stock Analyst at Oppenheimer
(1.38)
# 3,778
Out of 4,994 analysts
19
Total ratings
40%
Success rate
-1.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Rated: Buy | $8 → $5 | $1.22 | +311.52% | 2 | Sep 22, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 → $40 | $25.57 | +56.43% | 3 | Sep 22, 2026 | |
| QNCX Quince Therapeutics | Reiterated: Buy | $82 | $31.35 | +161.56% | 2 | Aug 17, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 | $4.66 | +372.10% | 3 | Aug 12, 2026 | |
| IKT Inhibikase Therapeutics | Reiterated: Buy | $5 | $2.31 | +116.45% | 2 | Aug 12, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $97 → $100 | $77.08 | +29.74% | 3 | Aug 12, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $9 | $2.08 | +332.69% | 3 | Jul 20, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $44.51 | +14.58% | 1 | Jul 9, 2026 |
Connect Biopharma Holdings
Sep 22, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.22
Upside: +311.52%
Tyra Biosciences
Sep 22, 2026
Reiterated: Buy
Price Target: $50 → $40
Current: $25.57
Upside: +56.43%
Quince Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $82
Current: $31.35
Upside: +161.56%
BridgeBio Oncology Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $22
Current: $4.66
Upside: +372.10%
Inhibikase Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $5
Current: $2.31
Upside: +116.45%
Tarsus Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: $97 → $100
Current: $77.08
Upside: +29.74%
InflaRx
Jul 20, 2026
Reiterated: Buy
Price Target: $9
Current: $2.08
Upside: +332.69%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $44.51
Upside: +14.58%